ASCENTAGE PHARMA
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

ASCENTAGE PHARMA Trademark

Serial Number: 90039971 • Registration: 6565245

ASCENTAGE PHARMA is a trademark filed by ASCENTAGE PHARMA (SUZHOU) CO., LTD. on July 7, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

ASCENTAGE PHARMA (SUZHOU) CO., LTD. (23 trademarks)

68 XINQING ROAD
SUZHOU 215000 , CN

Entity Type: 03

Jiangsu Ascentage Biomed Development Inc. (3 trademarks)

Rm 101, 1st Flr, Phase 1, New Drug Innov
Taizhou, Jiangsu 225300 , CN

Entity Type: 03

Trademark Details

Filing Date

July 7, 2020

Registration Date

November 23, 2021

Published for Opposition

September 7, 2021

Goods & Services

Medicines for dental purposes; chemical preparations for medical purposes for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; antibiotics; medicine for injection for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; medicinal tablets, for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; bulk drugs, namely, pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease sold in bulk; biochemical medicines for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; antiseptics; collyrium; suppositories being pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; plasters for medical purposes; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; medicated candy; candy for medical purposes; dietetic foods adapted for medical purposes; dietetic beverages adapted for medical purposes; dietetic preparations adapted for medical use; oil solutions, namely, medicinal oils; mineral food supplements; nutritional supplements; medicines for human purposes, namely, pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; bacterial poisons; pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemical-pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; biological preparations for medical purposes for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemical preparations for pharmaceutical purposes, for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease

Analysis of the mode of action of chemical combinations on animals; scientific research for medical purposes in the area of cancerous diseases; conducting early evaluations in the field of new pharmaceuticals; pharmaceutical research services; scientific investigations for medical purposes; chemical analysis services; biochemical research and analysis; chemical research services; working on and evaluation of chemical analyses; chemical research and analysis; working on and evaluation of chemical syntheses; chemical analysis; chemistry services in the nature of chemist services; chemical research; cosmetics research; structural and functional analysis of genomes; stem cell research services; biotechnology research; blood analysis services; genetic screening for scientific research purposes; biological cloning services; research and development services in the field of antibodies; genetic testing for scientific research purposes; bacteriological research and analysis; biomedical research services; medical research; drug discovery services; medical laboratory services; development of pharmaceutical preparations and medicines; medical research services; biological research and analysis; bacteriological research; biological research; conducting clinical trials for others; computer programming in the medical field; pharmaceutical product evaluation; research on the subject of pharmaceuticals

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 21, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Aug 21, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 21, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 21, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 21, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 21, 2025 COAR
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 2, 2025 ASGN
REGISTERED-PRINCIPAL REGISTER
Nov 23, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 7, 2021 NPUB
PUBLISHED FOR OPPOSITION
Sep 7, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 18, 2021 NONP
ELECTRONIC RECORD REVIEW COMPLETE
Aug 3, 2021 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Jul 30, 2021 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 28, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 28, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 28, 2021 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 28, 2021 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Apr 12, 2021 GNFN
FINAL REFUSAL E-MAILED
Apr 12, 2021 GNFR
FINAL REFUSAL WRITTEN
Apr 12, 2021 CNFR
ASSIGNED TO EXAMINER
Mar 23, 2021 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 3, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 3, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 2, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 20, 2020 GNRN
NON-FINAL ACTION E-MAILED
Oct 20, 2020 GNRT
NON-FINAL ACTION WRITTEN
Oct 20, 2020 CNRT
ASSIGNED TO EXAMINER
Oct 14, 2020 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Aug 5, 2020 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 4, 2020 NWOS
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Jul 27, 2020 AMPX
ASSIGNED TO LIE
Jul 27, 2020 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
Jul 13, 2020 PARI
NEW APPLICATION ENTERED
Jul 10, 2020 NWAP